Drugs / SHR-1916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04842630 | Apr 2021 → Nov 2022 | cancer of unknown primary site | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04842630 ↗ |